In conclusion, the present study demonstrated that legumain affects the progression of atherosclerosis by modulating CD4+ T cell biology, which is a novel immunological molecular mechanism of legumain in the pathogenesis of atherosclerosis. The gene discussed is CD4; the disease is atherosclerosis.